TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03527758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flo TracIQ with HPI software
Description: Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
Study: NCT03932695

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
Study: NCT01233375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01
Description: 1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles.
Study: NCT05259592

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen \& Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen \& Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.
Study: NCT02199171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given via HIPEC
Study: NCT02862158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDT visual field

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard HVF
Study: NCT04186819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPSMA-7.3 (18F) Injection
Description: Radioligand for PET CT scanning
Study: NCT02848976

Intervention type: OTHER
Intervention: Re-training to effort (RE)
Description: The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions

Intervention type: OTHER
Intervention: Re-training to effort (RE)
Description: The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions

Intervention type: OTHER
Intervention: Re-training to effort (RE)
Description: The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
Study: NCT00614016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ST20
Description: single administration of oral dosage form
Study: NCT03406507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
Study: NCT01282918

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation w/o DF test
Description: ICD implantation without Defibrillation Test
Study: NCT01988870

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative Radiation Therapy (IORT)
Description: IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
Study: NCT00458133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
Study: NCT00848328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
Study: NCT01282918

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation with DF test
Description: ICD implantation with DF test according to standardized procedure
Study: NCT03576625

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Sunflower Oil
Description: Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buglossoides Oil
Description: Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
Study: NCT01540019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paullinia cupana
Description: 50mg of Paullinia cupana as capsule, twice daily
Study: NCT03852771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cirvo(TM) therapy
Description: The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
Study: NCT03537534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Jet Injector
Description: Applying Lidocaine following endourologic procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Applying surgilube following endourologic procedure
Study: NCT02574234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of apelin and inflammatory cytokines
Description: A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of cognitive functions
Description: Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid sampling cerebrospinal
Description: Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
Study: NCT00848328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
Study: NCT00458133

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
Study: NCT02574234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative delirium research
Description: Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Residual cognitive dysfunction research
Description: Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
Study: NCT01463631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3007113
Description: Administered orally
Study: NCT03310281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOLD: Videogame
Description: Videogame-like digital therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOLD: Videogame
Description: Videogame-like digital therapy
Study: NCT02847078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart phone app
Description: App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.

Intervention type: DEVICE
Group type: OTHER
Intervention: A guideline booklet
Description: A guideline booklet with general advice on secondary prevention of coronary artery disease.
Study: NCT00823875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol group
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol group
Description: Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol + Probucol group
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner

Intervention type: DRUG
Group type: OTHER
Intervention: control group
Description: routine treatment
Study: NCT03604198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relacorilant
Description: CORT125134 is supplied as capsules for oral dosing.
Study: NCT02603341

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon
Description: Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton
Description: Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
Study: NCT02854982

Intervention type: PROCEDURE
Intervention: therapeutic management of the prostate Cancer as usual
Study: NCT00575081

Intervention type: DEVICE
Intervention: Stereotactic brain procedures
Description: Stereotactic brain procedures
Study: NCT03349125

Intervention type: BEHAVIORAL
Intervention: Collar On

Intervention type: BEHAVIORAL
Intervention: Collar Off
Study: NCT04098809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 16 French urinary catheter
Description: 16 French urinary catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20 French urinary catheter
Description: 20 French urinary catheter
Study: NCT03415815

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Radical resection of esophageal cancer
Study: NCT00715052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: 40 consecutive one hour treatments at 1.5 ATA with 100% O2
Study: NCT03009474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-30060
Description: Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge tab 5/160mg, Crestor tab 10mg
Description: Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
Study: NCT00763126

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stress level
Description: Stress levels

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stress level
Description: Stress levels
Study: NCT01013207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Pre Nexus (S9)
Description: This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexus (S9)
Description: The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Post Nexus (S9)
Description: After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
Study: NCT04260789

Intervention type: DEVICE
Group type: OTHER
Intervention: Seraph 100,The Microbind Affinity Blood Filter
Description: Treatment with Seraph 100 in one arm
Study: NCT00900328

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative Studies
Study: NCT01866605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous midazolam 0.3 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline injection will be given to groups not receiving midazolam

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger
Description: Forced air warming
Study: NCT02874235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receptive music therapy
Description: 16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological treatment
Description: 16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
Study: NCT04352075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous biologic drug of innovative therapy /cell therapy drug
Description: Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous biologic drug of innovative therapy /cell therapy drug
Description: Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous biologic drug of innovative therapy /cell therapy drug
Description: Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
Study: NCT02333175

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist review
Description: Specialist review with individually tailored treatment strategies suggested by specialist
Study: NCT03432130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural training program
Description: 15-week experimental structural training protocol
Study: NCT01331525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
Study: NCT04141566

Intervention type: PROCEDURE
Intervention: Perineal pseudocontinent colostomy
Description: The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses.

Intervention type: PROCEDURE
Intervention: Permanent left iliac colostomy
Description: After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
Study: NCT01387958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03118401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ritual of stool
Description: During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice
Description: During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
Study: NCT02525575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Life Force Group Treatment
Description: PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide.
Study: NCT02736331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: Treatment 1 Beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Treatment 2
Description: Treatment 2 Beverage
Study: NCT00594958

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Description: 6 mcg, intramuscularly \[i.m.\], 0.5 mL
Study: NCT00004893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study: NCT00570310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pregabalin
Description: pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
Study: NCT01372566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvest PRP Separation System
Description: Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
Study: NCT01372566

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline injection
Description: Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
Study: NCT02741596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
Study: NCT03329846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified day
Study: NCT04583995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix M1-Adjuvant
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix M1-Adjuvant
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Licensed seasonal influenza vaccine
Description: Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed seasonal influenza vaccine
Description: Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
Study: NCT01946217

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies